Intravenous β‐lactam antibiotics remain a cornerstone in the management of bacterial
infections due to their broad spectrum of activity and excellent tolerability. β‐lactams are well …

The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly
altered due to the dynamic, unpredictable pathophysiological changes that occur in critical …

Pseudomonas aeruginosa is characterized by a notable intrinsic resistance to antibiotics,
mainly mediated by the expression of inducible chromosomic β-lactamases and the …

Continuous infusion of β-lactam antibiotics has been widely promoted to optimise their time-
dependent activity. Increasing evidence is emerging suggesting potential benefits in patient …

Patients admitted to Intensive Care Units (ICUs) are at very high risk of developing severe
nosocomial infections. Consequently, antimicrobials are among the most important and …

There is controversy over whether traditional intermittent bolus dosing or continuous infusion
of beta-lactam antibiotics is preferable in critically ill patients. No significant difference …

Killing of bacteria by β-lactam antibiotics is maximal at around four times the minimum
inhibitory concentration in vitro. To ensure an optimal effect when treating severe infections …

Management of nosocomial pneumonia is frequently complicated by bacterial resistance.
Extended infusions of beta-lactams are increasingly being used to improve clinical …

Infections and related sepsis are two of the most prevalent issues in the care of critically ill
patients, with mortality as high as 70%. Appropriate antibiotic selection, as well as adequate …

The pharmacokinetics (PK) of antimicrobial agents administered to critically ill patients
exhibit marked variability. This variability results from pathophysiological changes that occur …